Alnylam, German Group Settle RNA Patent App Case

Law360, New York (March 15, 2011, 6:12 PM EDT) -- Alnylam Pharmaceuticals Inc. and a German research organization on Tuesday settled their contract suit against a Massachusetts-based biomedical research group and a college trustee board over the prosecution of two families of RNA interference patent applications.

Attorneys for plaintiffs Alnylam and the Max Planck Society and defendants the Whitehead Institute for Biomedical Research and the board of trustees of the University of Massachusetts filed a stipulation of dismissal in the U.S. District Court for the District of Massachusetts.

The Massachusetts Institute of Technology, which had been...
To view the full article, register now.